+

WO1995003809A3 - Inhibiteurs de tumeurs - Google Patents

Inhibiteurs de tumeurs Download PDF

Info

Publication number
WO1995003809A3
WO1995003809A3 PCT/GB1994/001676 GB9401676W WO9503809A3 WO 1995003809 A3 WO1995003809 A3 WO 1995003809A3 GB 9401676 W GB9401676 W GB 9401676W WO 9503809 A3 WO9503809 A3 WO 9503809A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
manufacture
treating tumours
glucokinase
glucokinase inhibitors
Prior art date
Application number
PCT/GB1994/001676
Other languages
English (en)
Other versions
WO1995003809A2 (fr
Inventor
Mary Board
Eric Arthur Newsholme
Original Assignee
Isis Innovation
Mary Board
Eric Arthur Newsholme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, Mary Board, Eric Arthur Newsholme filed Critical Isis Innovation
Priority to AU72692/94A priority Critical patent/AU7269294A/en
Publication of WO1995003809A2 publication Critical patent/WO1995003809A2/fr
Publication of WO1995003809A3 publication Critical patent/WO1995003809A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé d'inhibition de la croissance de cellules tumorales qui consiste à mettre ces dernières en contact avec un inhibiteur de la glucokinase. L'enzyme glucokinase que l'on ne trouve que dans les cellules-β du foie et du pancréas s'avère active dans les cellules tumorales.
PCT/GB1994/001676 1993-07-30 1994-08-01 Inhibiteurs de tumeurs WO1995003809A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU72692/94A AU7269294A (en) 1993-07-30 1994-08-01 Use of glucokinase inhibitors for the manufacture of a medicament for treating tumours

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9315846.7 1993-07-30
GB939315846A GB9315846D0 (en) 1993-07-30 1993-07-30 Tumour inhibitors

Publications (2)

Publication Number Publication Date
WO1995003809A2 WO1995003809A2 (fr) 1995-02-09
WO1995003809A3 true WO1995003809A3 (fr) 1995-03-16

Family

ID=10739734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/001676 WO1995003809A2 (fr) 1993-07-30 1994-08-01 Inhibiteurs de tumeurs

Country Status (3)

Country Link
AU (1) AU7269294A (fr)
GB (1) GB9315846D0 (fr)
WO (1) WO1995003809A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404162B2 (en) 2005-05-31 2016-08-02 Mars, Incorporated Feline probiotic bifidobacteria and methods
US9415083B2 (en) 2004-05-10 2016-08-16 Mars, Incorporated Method for decreasing inflammation and stress in a mammal
US9427000B2 (en) 2005-05-31 2016-08-30 Mars, Incorporated Feline probiotic lactobacilli composition and methods
US9580680B2 (en) 2003-12-19 2017-02-28 Mars, Incorporated Canine probiotic bifidobacterium pseudolongum

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7666459B2 (en) 2001-09-12 2010-02-23 The Procter & Gamble Company Pet food compositions
WO2005025581A1 (fr) * 2003-09-17 2005-03-24 Third Military Medical University, Chinese People's Liberation Army, P.R. Of China Utilisation de la n-acetyl-d-aminoglycosamine pour la preparation de medicaments de traitement du cancer et des metastases
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
FR2869541B1 (fr) 2004-04-30 2007-12-28 Expanscience Sa Lab Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee
JP4943839B2 (ja) * 2004-05-26 2012-05-30 株式会社希少糖生産技術研究所 血管新生抑制剤
GEP20135783B (en) 2008-05-16 2013-03-11 Takeda California Inc Glucokinase activators
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
FR2953722B1 (fr) 2009-12-16 2012-03-09 Expanscience Lab Composition comprenant au moins un sucre en c7 pour le traitement de l'alopecie, pour le traitement cosmetique des phaneres, et pour le soin des cheveux, cils ou ongles
WO2012012390A1 (fr) 2010-07-19 2012-01-26 Marvphyt Development Llc Composition botanique et procédés de fabrication et utilisation
FR3001889B1 (fr) * 2013-02-11 2021-02-12 Expanscience Lab Utilisation d'une composition comprenant un perseose d'avocat dans la protection des cellules souches epidermiques .

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249008A2 (fr) * 1986-05-09 1987-12-16 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Utilisation de monosaccharides spécifiques pour la préparation d'un médicament pour la prévention des métastases de tumeurs malignes
EP0372730A2 (fr) * 1988-11-18 1990-06-13 University Of British Columbia N-acétylglucosamine comme agent cytoprotectif

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249008A2 (fr) * 1986-05-09 1987-12-16 Pulverer, Gerhard, Prof. Dr.Dr.h.c. Utilisation de monosaccharides spécifiques pour la préparation d'un médicament pour la prévention des métastases de tumeurs malignes
EP0372730A2 (fr) * 1988-11-18 1990-06-13 University Of British Columbia N-acétylglucosamine comme agent cytoprotectif

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D.HERNANDEZ ET AL.: "Mannose toxicity in Ehrlich ascites tumor cells", BIOCHEM. CELL BIOL., vol. 67, no. 6, 1989, pages 311 - 314 *
KEDAR N. PRASAD: "Differentiation of neuroblastoma cells in culture", BIOLOGICAL REVIEWS, vol. 50, no. 2, 1975, pages 129 - 165 *
MARIA LUZ CARDENAS ET AL.: "Suppression of kinetic cooperativity of hexokinase D (glucokinase) by competitive inhibitors", EUR.J.BIOCHEM, vol. 145, no. 1, 1984, pages 163 - 171 *
WALTER S. ZAWALICH ET AL.: "Interleukin-1alpha excerts glucose-dependent stimulatory and inhibitory effects on islet cell phosphoinositide hydrolysis and insulin secretion", ENDOCRINOLOGY, vol. 124, no. 5, 1989, pages 2350 - 2357 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580680B2 (en) 2003-12-19 2017-02-28 Mars, Incorporated Canine probiotic bifidobacterium pseudolongum
US9415083B2 (en) 2004-05-10 2016-08-16 Mars, Incorporated Method for decreasing inflammation and stress in a mammal
US9404162B2 (en) 2005-05-31 2016-08-02 Mars, Incorporated Feline probiotic bifidobacteria and methods
US9427000B2 (en) 2005-05-31 2016-08-30 Mars, Incorporated Feline probiotic lactobacilli composition and methods

Also Published As

Publication number Publication date
AU7269294A (en) 1995-02-28
GB9315846D0 (en) 1993-09-15
WO1995003809A2 (fr) 1995-02-09

Similar Documents

Publication Publication Date Title
WO1995003809A3 (fr) Inhibiteurs de tumeurs
WO1993021942A3 (fr) Utilisation d'inhibiteurs de metalloprotease matricielle (mmp)
MY133569A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
AU2379200A (en) Absorbent article
IL109177A0 (en) Inhibitor of stem cell proliferation and uses thereof
MY129973A (en) Sulphonylbenzyl-substituted pyridones.
EP1050540A3 (fr) Inhibiteurs de dipeptidyl-aminopeptidase de type IV
EP0352864A3 (fr) Composés actifs comme inhibiteurs de la synthèse de cholestérol
DK0774005T3 (da) Overfladeudtrykkelse af enzymer i genorienteret prodrug-terapi
AU1002497A (en) Method of inhibiting transformation, growth and metastasis of cells in which purine metabolic enzyme activity is elevated
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
AU7418794A (en) Antiulcer agent and adhesion inhibitor for
DE69532813D1 (de) Inhibitor der stammzellenproliferation und dessen verwendung
WO1998022098A3 (fr) Inhibiteurs de cpp32 destines a reguler l'apoptose
EP1167354A3 (fr) Huperzine A racémique
WO2001091774A3 (fr) Traitement des ulceres chroniques
AU3954093A (en) Enzyme products for use in the improvement of feed value and conservation of fibrous crops
AU563831B2 (en) N-(2-amino-3,5-dibromobenzyl)- trans-4-amino-cyclohexanol derivatives
AU8742198A (en) Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
NZ331843A (en) Use of carbonic anhydrase inhibitors for treating macular edema or macular degeneration
WO2000047231A3 (fr) Nouvelle inhibition antisens de rad51
AU4290796A (en) 7-alkylidene cephalosporanic acid derivatives and methods ofusing the same
AU4057789A (en) Method for using protease inhibitors to treat and/or prevent pancreatitis
WO2003051312A3 (fr) E2f et cancerotherapie
MD861G2 (ro) Procedeu şi compoziţie farmaceutică pentru distrugerea celulelor tumorale ale mamiferelor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP NZ US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP NZ US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载